<DOC>
	<DOCNO>NCT00922402</DOCNO>
	<brief_summary>The main purpose study validate intensive protocol insulin infusion subsequent subcutaneous insulin administration support continuous glucose monitoring , addition reference finger-stick value .</brief_summary>
	<brief_title>Heart &amp; Diabetes - Feasibility Study</brief_title>
	<detailed_description>Heart failure common disease ( prevalence worldwide : 22 million ; incidence worldwide : 2 million ; prevalence Italy : 750.000 ; incidence Italy : 170.000 ) , affect 1-2 % overall population accounting significant proportion healthcare cost . Recurrent hospital admission represent majority disease-related cost . About 15-25 % patient HF diabetic : presence diabetes significantly worsens prognosis patient heart failure increase risk death 30 % compare subject without diabetes . The intensive control glycemia acute heart failure objective primary importance , obtain proper strategy patient management considerable organizational effort . In share protocol aim tight control glycemia , use Continuous Glucose Monitoring ( CGM ) expect allow easy management patient accurate implementation protocol . The main purpose study validate intensive protocol insulin infusion subsequent subcutaneous insulin administration support continuous glucose monitoring , addition reference finger-stick value .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Inclusion Criteria ( follow inclusion criterion must meet patient enrol study ) : acute heart failure , define accord current ESC Guidelines HbA1c &gt; 7.5 % admission Cardiology Unit glycemia &gt; 180 mg/dL admission Cardiology Unit patient sign Informed Consent Exclusion Criteria ( follow criterion meet , patient enrol study ) : heart failure acute infarction cardiogenic shock creatinemia &gt; 3.5 mg/dL admission hemodialytic therapy cirrhosis acute infective pathology cardiac revascularization hospitalization precede 3 month life expectance &lt; 12 month age &lt; 18 year pregnant woman inform consent sign subject include protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Acute</keyword>
	<keyword>heart failure</keyword>
	<keyword>hyperglycemia</keyword>
	<keyword>Acute heart failure high level glycemia</keyword>
</DOC>